SecBot SecBot
8-K ·Filed Aug 6, 2026

IMCR

Immunocore Holdings plc
MIXED
Impact 5/10
Horizonweeks Processed3mo ago SEC0001671927-26-000020
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Revenue growth remains strong and losses are narrowing, but the EPS miss relative to consensus may cause short-term pressure. The key catalyst is TEBE-AM Phase 3 data expected by end of 2026, a positive readout could significantly expand KIMMTRAK's addressable market into cutaneous melanoma. Monitor upcoming pipeline data presentations in H2 2026.

DirectionMixed
Confidencehigh
Horizonweeks

KIMMTRAK

▲ Bullish Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercialized (since January 2022). Label expansion into cutaneous melanoma depends on Phase 3 TEBE-AM data expected by end of 2026; if positive, an sBLA submission would follow, with potential approval in 2027-2028.
Next catalyst
None dated

What to watchThe key near-term catalyst is the Phase 3 TEBE-AM topline readout for KIMMTRAK in cutaneous melanoma, expected by end of 2026 (~4 months away). A positive result could double the addressable market; a negative readout would be a major setback. With ~16.4% of shares short and ~18.8 days to cover, a positive readout could trigger significant short-covering upside. Watch for enrollment completion announcements and any data updates at medical meetings in H2 2026.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$34.50
T+0 close · Aug 6, 2026 · via day close
Latest settled
−11.62%
T+60 · $30.49
Vs SPY
−9.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $34.50entry
  2. T+1 · 3mo ago −1.45%α −2.06% · $34.00
  3. T+5 · 3mo ago −0.87%α −2.08% · $34.20
  4. T+20 · 3mo ago +8.90%α +8.30% · $37.57
  5. T+60 · 18d ago −11.62%α −9.95% · $30.49
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immunocore reported Q2 2026 KIMMTRAK revenue of $115.9M (+18% YoY), beating consensus of $110.4M, but posted a small net loss of $0.8M ($-0.02 EPS) vs consensus expectations of $0.02 EPS. The EPS miss was driven by higher R&D spend on three Phase 3 trials. Cash position remains strong at $880M. Enrollment in the pivotal TEBE-AM trial for cutaneous melanoma is nearing completion with data possible by year-end.

Key Financial Metrics

EPS
−$0.02
est $0.02 · -200.0%
Revenue
$115.9M
est $110.4M · +5.0% · +18.3% YoY
Rating
strong miss

Key Facts

  • Q2 2026 KIMMTRAK net revenue $115.9M, up 18% YoY from $98.0M
  • Net loss of $0.8M ($-0.02 EPS) vs net loss of $10.3M ($-0.20 EPS) in Q2 2025
  • Revenue beat consensus of $110.4M; EPS missed consensus of $0.02
  • Cash, cash equivalents and marketable securities $880.2M as of June 30, 2026
  • Enrollment in Phase 3 TEBE-AM trial nearing target of 540 patients; topline data possible end of 2026
  • Phase 3 PRISM-MEL-301 (brenetafusp) and ATOM (adjuvant uveal melanoma) trials ongoing

Financial Impact

Revenue grew 18% YoY to $115.9M; net loss narrowed to $0.8M from $10.3M; EPS miss of -$0.04 vs consensus

revenueepsnet incomecash position

Risk Factors

  • KIMMTRAK is the sole revenue source; any sales disruption or competitive threat would materially impact financials
  • Clinical trial risks for TEBE-AM, PRISM-MEL-301, and ATOM trials
  • Expected $120M in sales-related rebate payments in H2 2026 could pressure cash flow

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
76% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001671927-26-000020
Document: imcr-20260806.htm0001671927-26-000020
Document: 0001671927-26-000020-index-headers.html0001671927-26-000020
Document: 0001671927-26-000020-index.html0001671927-26-000020
Document: 0001671927-26-000020.txt0001671927-26-000020
8-K Data (Synthetic)0001671927-26-000020

Track record

14 reports on IMCR

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +28.39% at T+60 after the May 31, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 9, 20267d ago SC 13G Neutral 4/10 Entry $32.38 Now $28.88 −10.81% settles Feb 8
  2. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $30.99 Now $28.88 −6.81% settles Feb 4
  3. Nov 6, 202610d ago 8-K Neutral 4/10 No price data
  4. Nov 6, 202610d ago Press Release Bearish 5/10 Entry $30.99 Now $28.88 +6.81% settles Feb 4
  5. Oct 29, 202618d ago Press Release Neutral 3/10 Entry $31.27 Now $28.88 −7.64% settles Jan 27
  6. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $29.48 Now $28.88 −2.04% settles Jan 12
  7. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $29.41 Now $28.88 −1.80% settles Jan 4
  8. Sep 14, 20269w ago 8-K Bullish 6/10 Entry $32.46 Now $28.88 −11.03% settles Dec 8
  9. Aug 6, 202614w ago 8-K Mixed 5/10 Viewing Entry $34.50 to $30.49 Now $28.88 −16.29% ▼ −11.62% −9.95% vs SPY
  10. May 31, 202624w ago Press Release Bullish 6/10 Entry $29.13 to $37.40 Now $28.88 −0.86% ▲ +28.39% +27.16% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens Wed (10h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026